Switchers, stratified by first TNFα inhibitor and by reason for switching therapy
| No. of patients initiating second treatment (switchers) | Switchers’ reason for withdrawing from first treatment | Patients withdrawing from second treatment | Reason for withdrawing from second treatment* |
|---|---|---|---|
| AE, Adverse event; LOE, lack of efficacy. | |||
| *Of the 81 patients who withdrew from second treatment, 51 initiated a third biological drug. | |||
| Infliximab n = 178 | LOE n = 80 (45%) | n = 36 | LOE n = 26 (31%) |
| AE n = 2 (2%) | |||
| Other n = 8 (9%) | |||
| AE n = 60 (34%) | n = 31 | LOE n = 16 (19%) | |
| AE n = 10 (12%) | |||
| Other n = 5 (6%) | |||
| Other n = 38 (21%) | n = 18 | ||
| Etanercept n = 18 | LOE n = 8 (44%) | n = 4 | LOE n = 3 (38%) |
| AE n = 0 (0%) | |||
| Other n = 1 (13%) | |||
| AE n = 4 (22%) | n = 1 | LOE n = 1 (13%) | |
| AE n = 0 (0%) | |||
| Other n = 0 (0%) | |||
| Other n = 6 (34%) | n = 3 | ||
| Adalimumab n = 39 | LOE n = 21 (54%) | n = 7 | LOR n = 6 (40%) |
| AE n = 1 (7%) | |||
| Other n = 0 (0%) | |||
| AE n = 8 (21%) | n = 2 | LOE n = 1 (7%) | |
| AE n = 1 (7%) | |||
| Other n = 0 (0%) | |||
| Other n = 10 (26%) | n = 6 | ||